The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

被引：0
|
作者：
Mary Jo Fidler
Cristina L. Fhied
Joanna Roder
Sanjib Basu
Selina Sayidine
Ibtihaj Fughhi
Mark Pool
Marta Batus
Philip Bonomi
Jeffrey A. Borgia
机构：
[1] Sections of Medical Oncology at Rush University Medical Center,Departments of Pathology and Cell & Molecular Medicine
[2] Pathology,undefined
[3] Rush University Medical Center,undefined
[4] Biodesix,undefined
[5] Inc,undefined
[6] Preventative Medicine,undefined
[7] Rush University Medical Center,undefined
[8] Cell and Molecular Medicine at Rush University Medical Center,undefined
[9] Rush University Medical Center,undefined
来源：
BMC Cancer | / 18卷
关键词：
Biomarker; Serum; Non-small cell lung cancer (NSCLC); Erlotinib; Luminex; VeriStrat;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients
    Sugimoto, Akira
    Kaneda, Hiroyasu
    Nagamine, Hiroaki
    Nakahama, Kenji
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Sawa, Kenji
    Tani, Yoko
    Mitsuoka, Shigeki
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    ANNALS OF ONCOLOGY, 2023, 34 : S1451 - S1451
  • [22] Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy
    Suzawa, Ken
    Soh, Junichi
    Takahashi, Yuta
    Sato, Hiroki
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Kanazawa, Susumu
    Kiura, Katsuyuki
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    SURGERY TODAY, 2019, 49 (07) : 601 - 609
  • [23] High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients
    Wei, Long-Xiao
    Zhou, Run-Suo
    Xu, Hai-Feng
    Wang, Jun-Yan
    Yuan, Meng-Hui
    TUMOR BIOLOGY, 2013, 34 (02) : 941 - 946
  • [24] Dysbiosis of lower respiratory tract microbiome are associated with proinflammatory states in non-small cell lung cancer patients
    Li, Yangqian
    Rao, Guanhua
    Zhu, Guonian
    Cheng, Cheng
    Yuan, Lijuan
    Li, Chengpin
    Gao, Jianpeng
    Tang, Jun
    Wang, Zhoufeng
    Li, Weimin
    THORACIC CANCER, 2024, 15 (02) : 111 - 121
  • [25] Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
    Akerley, Wallace L.
    Arnaud, Alix M.
    Reddy, Bibas
    Page, Ray D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (06) : 1091 - 1097
  • [26] The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy
    Lee, Siow Ming
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Rudd, Robin
    Ngai, Yenting
    Edwards, Alex
    Hackshaw, Allan
    EUROPEAN JOURNAL OF CANCER, 2019, 120 : 86 - 96
  • [27] Serum hepcidin and iron are associated with non-small cell lung cancer stage
    Sato, Kento
    Shibata, Yoko
    Inoue, Sumito
    Igarash, Akirai
    Tokairin, Yoshikane
    Yamauchi, Keiko
    Kimura, Tomomi
    Nemoto, Takako
    Sato, Masamichi
    Nakano, Hiroshi
    Abe, Yuki
    Kubota, Isao
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [28] Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage
    Chen, Qian
    Wang, Li
    Ma, Yuchao
    Wu, Xianning
    Jin, Longyu
    Yu, Fenglei
    THORACIC CANCER, 2014, 5 (01) : 14 - 24
  • [29] VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    Carbone, David P.
    Salmon, J. Stuart
    Billheimer, Dean
    Chen, Heidi
    Sandler, Alan
    Roder, Heinrich
    Roder, Joanna
    Tsypin, Maxim
    Herbst, Roy S.
    Tsao, Anne S.
    Tran, Hai T.
    Dang, Thao P.
    LUNG CANCER, 2010, 69 (03) : 337 - 340
  • [30] Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?
    Ruiz, Jimmy
    Petty, W. Jeffrey
    ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (03)
12345